Skip to main content
Erschienen in: Clinical & Experimental Metastasis 4/2008

01.06.2008 | Research Paper

First surgical tumour reduction of peritoneal surface malignancy in a rat’s model

verfasst von: Jens Hartmann, Maik Kilian, Vladimir Atanassov, Chris Braumann, Juergen Ordemann, Christoph A. Jacobi

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Surgical therapy of peritoneal surface malignancy from colorectal origin in combination with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) has now become an established treatment approach in very few specialised centres. A peritonectomy procedure is possible to perform with additional HIPEC in patients. An experimental model to simulate peritonectomy procedure and HIPEC does not exist so far in rats. Nevertheless, animal models seem to be very important for evaluation of new therapeutic opportunities and toxicity of different multimodal therapies. In a first step we analysed the surgical tumour debulking of peritoneal surface malignancy in rats. A peritoneal surface malignancy from colonic origin was induced in 75 male BD IX rats. Twenty one days after induction of peritoneal surface malignancy rats were randomised and animals intend to create an operation with surgical tumour debulking. There was no tumour growth in two animals. The aim of the peritonectomy procedure was the complete tumour reduction. In this study the results of the surgical approach will be described. A complete tumour reduction (R0) was achieved in 34 animals. In 39 rats a macroscopic tumour deposit was left behind (R2). The intraoperative experimental Peritoneal Cancer Index (ePCI) was used to describe tumour weight and number of tumour inoculations. Both parameters were found to be dependent factors of complete tumour reduction. Six animals died due to therapeutical interventions. Surgical tumour debulking in rats with peritoneal surface malignancy is possible with high reliability and a low mortality rate. This animal model could be an important step for investigation of multimodal treatment options and toxicity in treatment regimens of peritoneal surface malignancy.
Literatur
2.
Zurück zum Zitat Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intra-peritoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 12:3737–3743CrossRef Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intra-peritoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 12:3737–3743CrossRef
3.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292PubMedCrossRef Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292PubMedCrossRef
4.
Zurück zum Zitat Ismail M, Henklein P, Huang X et al (2006) Identification of HIV-1 Tat peptides for future therapeutic angiogenesis. Eur J Haematol 77(2):157–165PubMedCrossRef Ismail M, Henklein P, Huang X et al (2006) Identification of HIV-1 Tat peptides for future therapeutic angiogenesis. Eur J Haematol 77(2):157–165PubMedCrossRef
5.
Zurück zum Zitat Steller EP, Ottow RT, Matthews W et al (1985) Recombinant interleukin-2 and adoptively transferred lymphokine-activated killer cells in the treatment of experimental peritoneal carcinomatosis. Surg Forum 36:390–392 Steller EP, Ottow RT, Matthews W et al (1985) Recombinant interleukin-2 and adoptively transferred lymphokine-activated killer cells in the treatment of experimental peritoneal carcinomatosis. Surg Forum 36:390–392
6.
Zurück zum Zitat Brodsky JT, Cohen AM (1991) Peritoneal seeding following potentially curative resection of colonic carcinoma: implications of adjuvant therapy. Dis Colon Rectum 34(8):723–727PubMedCrossRef Brodsky JT, Cohen AM (1991) Peritoneal seeding following potentially curative resection of colonic carcinoma: implications of adjuvant therapy. Dis Colon Rectum 34(8):723–727PubMedCrossRef
7.
Zurück zum Zitat Pelz JOW, Doerfer J, Hohenberger W et al (2005) A new survival model for intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 5:65CrossRef Pelz JOW, Doerfer J, Hohenberger W et al (2005) A new survival model for intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer 5:65CrossRef
8.
Zurück zum Zitat Los G, Siminia P, Wondergerem J et al (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472–477PubMedCrossRef Los G, Siminia P, Wondergerem J et al (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27:472–477PubMedCrossRef
9.
Zurück zum Zitat Hribaschek A, Pross M, Ridwelski K et al (2004) Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis. Zentralbl Chir 129(4):328–334PubMedCrossRef Hribaschek A, Pross M, Ridwelski K et al (2004) Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis. Zentralbl Chir 129(4):328–334PubMedCrossRef
10.
Zurück zum Zitat Veenhuizen RB, Marijnissen JP, Kenemans P et al (1996) Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer 73(11):1387–1392PubMed Veenhuizen RB, Marijnissen JP, Kenemans P et al (1996) Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma. Br J Cancer 73(11):1387–1392PubMed
11.
Zurück zum Zitat Balague C, Braumann C, Fuhrer K et al (2001) Validation of a new experimental model of colon cancer. Surg Endosc 15:833–836PubMedCrossRef Balague C, Braumann C, Fuhrer K et al (2001) Validation of a new experimental model of colon cancer. Surg Endosc 15:833–836PubMedCrossRef
12.
Zurück zum Zitat Ordemann J, Hoeflich C, Braumann C et al (2005) Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cells. Zentralbl Chir 130(5):405–409PubMedCrossRef Ordemann J, Hoeflich C, Braumann C et al (2005) Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cells. Zentralbl Chir 130(5):405–409PubMedCrossRef
13.
Zurück zum Zitat Braumann C, Ordemann J, Kilian M et al (2003) Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 20(5):387–394PubMedCrossRef Braumann C, Ordemann J, Kilian M et al (2003) Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 20(5):387–394PubMedCrossRef
14.
Zurück zum Zitat Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):278–285PubMedCrossRef Glehen O, Mohamed F, Sugarbaker PH (2004) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 240(2):278–285PubMedCrossRef
15.
Zurück zum Zitat Elias D, Blot F, El Otmany A et al (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92(1):71–76PubMedCrossRef Elias D, Blot F, El Otmany A et al (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92(1):71–76PubMedCrossRef
16.
Zurück zum Zitat Boni L, Benevento A, Dionigi G et al (2005) Injection of colorectal cancer cells in mesenteric and antimesenteric sides of the colon results in different patterns of metastatic diffusion: an experimental study in rats. World J Surg Oncol 3:69PubMedCrossRef Boni L, Benevento A, Dionigi G et al (2005) Injection of colorectal cancer cells in mesenteric and antimesenteric sides of the colon results in different patterns of metastatic diffusion: an experimental study in rats. World J Surg Oncol 3:69PubMedCrossRef
Metadaten
Titel
First surgical tumour reduction of peritoneal surface malignancy in a rat’s model
verfasst von
Jens Hartmann
Maik Kilian
Vladimir Atanassov
Chris Braumann
Juergen Ordemann
Christoph A. Jacobi
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 4/2008
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9150-x

Weitere Artikel der Ausgabe 4/2008

Clinical & Experimental Metastasis 4/2008 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.